![](https://ml.globenewswire.com/media/2a6188f6-e089-42bc-aa98-a7bc4c093bff/small/qkfkfcovarztbiz4etb9avuqqmn1580490657950-200x200-png.png)
Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable ...
FDA confirmed resubmission can occur without delay FDA confirmed additional GMP and/or BIMO inspections may occur after resubmission Elevar plans to resubmit as soon as possible FORT LEE, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc …